According to KEYNOTE – 028, pembrolizumab monotherapy showed limited antitumour activity in pretreated PDL-1 positive NEN with an ORR of only 12% in carcinoid tumours and 6.3% in pancreatic NEN [52]. This evidence concerns the gene CD274 and pancreatic neuroendocrine neoplasm.